Duke University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).

1,725 total trials 187 currently recruiting 1244 completed early-phase tilt top decile by trial count

Duke University: 1,725 sponsored US clinical trials, 187 recruiting.

Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.

Top-decile sponsor footprint

Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 55/100

1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,725 total, page 15 of 35

COMPLETED NA

Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD

NCT03216512

TERMINATED NA

Reach Home and Read

NCT03699592

COMPLETED NA

The Influence of a Cognitive Behavioral Approach on Changing Patient Expectations in Shoulder Pain

NCT03353272

TERMINATED Phase 4

Pain Perception During Vulvar Biopsy

NCT03654417

TERMINATED NA

Patient- and Task-specific Radiation Dose Optimization for Pediatric Abdominopelvic CT Applications

NCT03429712

COMPLETED NA

The DETOURS Trial: De-escalating Empiric Treatment: Opting Out of Rx for Selected Patients With Suspected Sepsis - Opt-Out Protocol Trial

NCT03517007

COMPLETED NA

System for High-Intensity Evaluation During Radiotherapy

NCT04277650

COMPLETED NA

Neuromodulatory Treatments for Pain Management in TBI

NCT03418129

COMPLETED Phase 2

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

NCT03351114

COMPLETED

The Learning Registry

NCT03911284

COMPLETED

Bedside Optical Retinal Assessment of Hypoxic Ischemic Encephalopathy in Infants

NCT03640494

COMPLETED NA

Neuromodulation Therapy for Task-Specific Dystonia

NCT06422104

COMPLETED NA

Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation Study

NCT03775759

COMPLETED NA

Exercise Training to Promote Resilience to Chronic Lymphocytic Leukemia

NCT04950452

COMPLETED

Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields

NCT03501134

TERMINATED NA

Trial Comparing PLA to HIGRT (PROVE-HCC)

NCT03402607

COMPLETED Phase 2

The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products

NCT03492463

COMPLETED NA

Earplugs and Eye Masks for Reducing Delirium

NCT03471520

COMPLETED NA

Reducing Disparities in the Quality of Advance Care Planning for Older Adults

NCT03516994

TERMINATED Phase 4

Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism

NCT03196349

COMPLETED NA

Testing the Feasibility of the DASH Cloud Intervention Using Amazon Alexa

NCT03455946

COMPLETED Phase 4

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

NCT03530124

TERMINATED NA

Effexts OF THE Cleansweep Suction Catheter

NCT03486002

COMPLETED

Low Dose CT Distal Radius Fractures

NCT03423043

COMPLETED Phase 3

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

NCT03296813

COMPLETED Phase 2

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

NCT03434418

COMPLETED

Study of ALS Reversals 2: Genetic Analyses

NCT03464903

COMPLETED Phase 1

Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer

NCT03394885

COMPLETED NA

Digital Symptom Tracking, Patient Engagement and Quality of Life in GI Oncology Clinic Patients

NCT03459352

COMPLETED NA

Balanced (Egg) Protein During Obesity Reduction: Differential Responses of Insulin Resistance by Race

NCT03771261

COMPLETED NA

Active Recreation Through Community-Healthcare Engagement Study

NCT03246763

COMPLETED NA

Preventing Post-Vaccination Presyncope and Syncope in Adolescents Using Simple, Clinic-based Interventions: A Pilot Study

NCT03533829

COMPLETED NA

Collaboration to Promote Early Childhood Well Being in Families Experiencing Homelessness

NCT03530137

TERMINATED Phase 1

Gene-by-Stress Interactions in Intervention Studies Significance

NCT03011645

COMPLETED Phase 3

Project Q Pilot: Smoking Cessation for Light Smokers

NCT03416621

COMPLETED NA

Early Palliative Care Intervention in Malignant Glioma

NCT03471546

COMPLETED

Disease-Modifying Treatments for Myasthenia Gravis

NCT03490539

COMPLETED Phase 4

Evaluation of Utility of Ultrasound Guided iPACK Block for Knee Extension After Total Knee Arthroplasty.

NCT03353233

COMPLETED Phase 4

Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension

NCT03390426

COMPLETED

SER Hispano Longitudinal Study

NCT03527654

COMPLETED Phase 1

Abdominal Nerve Blockade in Chronic Heart Failure.

NCT03453151

COMPLETED NA

Human Gut Microbiota and Prebiotic Response

NCT03595306

COMPLETED

REACH Implicit Bias Training Project

NCT03415308

COMPLETED NA

Physical Activity in Men Newly Diagnosed With Prostate Cancer: A Feasibility Study

NCT03331458

COMPLETED

Contributing Factors in the Pathobiology of Airway Remodeling in Obesity

NCT03115632

COMPLETED Phase 2

Metoclopramide Versus Placebo for GJ Placement

NCT03331965

COMPLETED NA

Low Cost OCT for Point of Care

NCT03323307

COMPLETED Early Phase 1

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075

NCT03248947

COMPLETED NA

Lingual Muscle Training in Late-Onset Pompe Disease (LOPD)

NCT03255213

COMPLETED

Bilateral Brain Dynamics in Cognition and Aging

NCT03224988

← Previous Page 15 of 35 Next →

Phase Distribution

PhaseTrial count
Phase 1 136
Phase 2 175
Phase 3 41
Phase 4 134

What is open in the Duke University pipeline

187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).

Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).

Top condition: Obesity (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Duke University: open-pipeline peers nationwide

Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,5002,000 5%10%15%20% Total trials Recruiting share Duke UniversityUniversity of California, San FranciscoStanford UniversityVA Office of Research and DevelopmentPfizerCarnegie Mellon UniversityCAMC Health SystemUConn HealthHartford Hospital
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,725 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

What to do with this Duke University page

1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.

  • 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.